Therapeutic antibodies and infectious diseases, Tours, France, November 20−22, 2012

References

• Therapeutic Antibodies and Infectious Diseases [Internet]. Tours, France: Therapeutic Antibodies and Infectious Diseases: 2010 [cited 2013 June 3]. Available at: http://taid.fr/?lang=en..
   Google Scholar
• Laboratoire d’excellence MAbImprove | Optimisation du développement des anticorps monoclonaux thérapeutiques [Internet]. Tours, France: LabEx MABImprove: 2013 [cited 2013 March 27]. Available at: http://mabimprove.univ-tours.fr/?lang=en.
   Google Scholar
• Infectiologie région Centre [Internet]. Tours, France: Le cluster de recherche en infectiologie de la région Centre: 16 May 2013 [cited 2013 March 27]. Available at: http://www.infectiologie-regioncentre.fr/Presentation/Le-cluster-de-recherche-en-infectiologie-de-la-region-Centre.
   Google Scholar
• Laffly E, Danjou L, Condemine F, Vidal D, Drouet E, Lefranc MP, et al. Selection of a macaque Fab with framework regions like those in humans, high affinity, and ability to neutralize the protective antigen (PA) of Bacillus anthracis by binding to the segment of PA between residues 686 and 694. Antimicrob Agents Chemother 2005; 49:3414 - 20; http://dx.doi.org/10.1128/AAC.49.8.3414-3420.2005; PMID: 16048955
   PubMed Web of Science ®Google Scholar
• Laffly E, Pelat T, Cédrone F, Blésa S, Bedouelle H, Thullier P. Improvement of an antibody neutralizing the anthrax toxin by simultaneous mutagenesis of its six hypervariable loops. J Mol Biol 2008; 378:1094 - 103; http://dx.doi.org/10.1016/j.jmb.2008.03.045; PMID: 18423488
   PubMed Web of Science ®Google Scholar
• Janssens R, Dekker S, Hendriks RW, Panayotou G, van Remoortere A, San JK, et al. Generation of heavy-chain-only antibodies in mice. Proc Natl Acad Sci U S A 2006; 103:15130 - 5; http://dx.doi.org/10.1073/pnas.0601108103; PMID: 17015837
   PubMed Web of Science ®Google Scholar
• Gauduchon V, Werner S, Prévost G, Monteil H, Colin DA. Flow cytometric determination of Panton-Valentine leucocidin S component binding. Infect Immun 2001; 69:2390 - 5; http://dx.doi.org/10.1128/IAI.69.4.2390-2395.2001; PMID: 11254598
   PubMed Web of Science ®Google Scholar
• Kohler PL, Greenwood SD, Nookala S, Kotb M, Kranz DM, Schlievert PM. Staphylococcus aureus isolates encode variant staphylococcal enterotoxin B proteins that are diverse in superantigenicity and lethality. PLoS One 2012; 7:e41157; http://dx.doi.org/10.1371/journal.pone.0041157; PMID: 22815951
   PubMedGoogle Scholar
• Bossart KN, Zhu Z, Middleton D, Klippel J, Crameri G, Bingham J, et al. A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection. PLoS Pathog 2009; 5:e1000642; http://dx.doi.org/10.1371/journal.ppat.1000642; PMID: 19888339
   PubMed Web of Science ®Google Scholar
• Bossart KN, Geisbert TW, Feldmann H, Zhu Z, Feldmann F, Geisbert JB, et al. A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge. Sci Transl Med 2011; 3:ra103; http://dx.doi.org/10.1126/scitranslmed.3002901; PMID: 22013123
   PubMed Web of Science ®Google Scholar
• Dye JM, Herbert AS, Kuehne AI, Barth JF, Muhammad MA, Zak SE, et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci U S A 2012; 109:5034 - 9; http://dx.doi.org/10.1073/pnas.1200409109; PMID: 22411795
   PubMed Web of Science ®Google Scholar
• Avril A, Froude JW, Mathieu J, Pelat T, Thullier P. Isolation of antibodies from non-human primates for clinical use. Curr Drug Discov Technol 2013; PMID: 23410051
   PubMedGoogle Scholar
• Horn MP, Zuercher AW, Imboden MA, Rudolf MP, Lazar H, Wu H, et al. Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11. Antimicrob Agents Chemother 2010; 54:2338 - 44; http://dx.doi.org/10.1128/AAC.01142-09; PMID: 20308370
   PubMed Web of Science ®Google Scholar
• Lu Q, Rouby JJ, Laterre PF, Eggimann P, Dugard A, Giamarellos-Bourboulis EJ, et al. Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia. J Antimicrob Chemother 2011; 66:1110 - 6; http://dx.doi.org/10.1093/jac/dkr046; PMID: 21398296
   PubMed Web of Science ®Google Scholar
• Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009; 113:3716 - 25; http://dx.doi.org/10.1182/blood-2008-09-179754; PMID: 19018092
   PubMed Web of Science ®Google Scholar
• Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 2012; 119:5640 - 9; http://dx.doi.org/10.1182/blood-2012-01-380121; PMID: 22535666
   PubMed Web of Science ®Google Scholar
• Jönsson F, Mancardi DA, Zhao W, Kita Y, Iannascoli B, Khun H, et al. Human FcγRIIA induces anaphylactic and allergic reactions. Blood 2012; 119:2533 - 44; http://dx.doi.org/10.1182/blood-2011-07-367334; PMID: 22138510
   PubMed Web of Science ®Google Scholar
• Mancardi DA, Albanesi M, Jönsson F, Iannascoli B, Van Rooijen N, Kang X, et al. The high-affinity human IgG receptor FcγRI (CD64) promotes IgG-mediated inflammation, anaphylaxis, and antitumor immunotherapy. Blood 2013; 121:1563 - 73; http://dx.doi.org/10.1182/blood-2012-07-442541; PMID: 23293080
   PubMed Web of Science ®Google Scholar
• Beerli RR, Bauer M, Schmitz N, Buser RB, Gwerder M, Muntwiler S, et al. Prophylactic and therapeutic activity of fully human monoclonal antibodies directed against influenza A M2 protein. Virol J 2009; 6:224; http://dx.doi.org/10.1186/1743-422X-6-224; PMID: 20025741
   PubMed Web of Science ®Google Scholar
• Beerli RR, Bauer M, Buser RB, Gwerder M, Muntwiler S, Maurer P, et al. Isolation of human monoclonal antibodies by mammalian cell display. Proc Natl Acad Sci U S A 2008; 105:14336 - 41; http://dx.doi.org/10.1073/pnas.0805942105; PMID: 18812621
   PubMed Web of Science ®Google Scholar
• Schmitz N, Beerli RR, Bauer M, Jegerlehner A, Dietmeier K, Maudrich M, et al. Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection. Eur J Immunol 2012; 42:863 - 9; http://dx.doi.org/10.1002/eji.201041225; PMID: 22531913
   PubMed Web of Science ®Google Scholar
• Michaud HA, Gomard T, Gros L, Thiolon K, Nasser R, Jacquet C, et al. A crucial role for infected-cell/antibody immune complexes in the enhancement of endogenous antiviral immunity by short passive immunotherapy. PLoS Pathog 2010; 6:e1000948; http://dx.doi.org/10.1371/journal.ppat.1000948; PMID: 20548955
   PubMed Web of Science ®Google Scholar
• Nasser R, Pelegrin M, Michaud H-A, Plays M, Piechaczyk M, Gros L. Long-lasting protective antiviral immunity induced by passive immunotherapies requires both neutralizing and effector functions of the administered monoclonal antibody. J Virol 2010; 84:10169 - 81; http://dx.doi.org/10.1128/JVI.00568-10; PMID: 20610721
   PubMed Web of Science ®Google Scholar
• Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, et al, Protocol G Principal Investigators. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009; 326:285 - 9; http://dx.doi.org/10.1126/science.1178746; PMID: 19729618
   PubMed Web of Science ®Google Scholar
• Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, et al, Protocol G Principal Investigators. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011; 477:466 - 70; http://dx.doi.org/10.1038/nature10373; PMID: 21849977
   PubMed Web of Science ®Google Scholar
• Moldt B, Rakasz EG, Schultz N, Chan-Hui PY, Swiderek K, Weisgrau KL, et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci U S A 2012; 109:18921 - 5; http://dx.doi.org/10.1073/pnas.1214785109; PMID: 23100539
   PubMed Web of Science ®Google Scholar
• Poignard P, Sabbe R, Picchio GR, Wang M, Gulizia RJ, Katinger H, et al. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity 1999; 10:431 - 8; http://dx.doi.org/10.1016/S1074-7613(00)80043-6; PMID: 10229186
   PubMed Web of Science ®Google Scholar
• Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF, Bournazos S, et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 2012; 492:118 - 22; http://dx.doi.org/10.1038/nature11604; PMID: 23103874
   PubMed Web of Science ®Google Scholar
• Jacobo-Molina A, Ding J, Nanni RG, Clark AD Jr., Lu X, Tantillo C, et al. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc Natl Acad Sci U S A 1993; 90:6320 - 4; http://dx.doi.org/10.1073/pnas.90.13.6320; PMID: 7687065
   PubMed Web of Science ®Google Scholar
• Both L, Banyard AC, van Dolleweerd C, Horton DL, Ma JK-C, Fooks AR. Passive immunity in the prevention of rabies. Lancet Infect Dis 2012; 12:397 - 407; http://dx.doi.org/10.1016/S1473-3099(11)70340-1; PMID: 22541629
   PubMed Web of Science ®Google Scholar
• Bakker AB, Python C, Kissling CJ, Pandya P, Marissen WE, Brink MF, et al. First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine 2008; 26:5922 - 7; http://dx.doi.org/10.1016/j.vaccine.2008.08.050; PMID: 18804136
   PubMed Web of Science ®Google Scholar
• Tarr AW, Lafaye P, Meredith L, Damier-Piolle L, Urbanowicz RA, Meola A, et al. An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission. Hepatology 2013; http://dx.doi.org/10.1002/hep.26430; PMID: 23553604
   PubMed Web of Science ®Google Scholar
• Zeisel MB, Koutsoudakis G, Schnober EK, Haberstroh A, Blum HE, Cosset FL, et al. Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology 2007; 46:1722 - 31; http://dx.doi.org/10.1002/hep.21994; PMID: 18000990
   PubMed Web of Science ®Google Scholar
• Zahid MN, Turek M, Xiao F, Thi VL, Guérin M, Fofana I, et al. The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination. Hepatology 2013; 57:492 - 504; http://dx.doi.org/10.1002/hep.26097; PMID: 23081796
   PubMed Web of Science ®Google Scholar
• Krieger SE, Zeisel MB, Davis C, Thumann C, Harris HJ, Schnober EK, et al. Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology 2010; 51:1144 - 57; http://dx.doi.org/10.1002/hep.23445; PMID: 20069648
   PubMed Web of Science ®Google Scholar
• Fofana I, Krieger SE, Grunert F, Glauben S, Xiao F, Fafi-Kremer S, et al. Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology 2010; 139:953 - 64, e1-4; http://dx.doi.org/10.1053/j.gastro.2010.05.073; PMID: 20685314
   PubMed Web of Science ®Google Scholar
• Frandsen TP, Naested H, Rasmussen SK, Hauptig P, Wiberg FC, Rasmussen LK, et al. Consistent manufacturing and quality control of a highly complex recombinant polyclonal antibody product for human therapeutic use. Biotechnol Bioeng 2011; 108:2171 - 81; http://dx.doi.org/10.1002/bit.23166; PMID: 21495017
   PubMed Web of Science ®Google Scholar
• King LA, Nogareda F, Weill FX, Mariani-Kurkdjian P, Loukiadis E, Gault G, et al. Outbreak of Shiga toxin-producing Escherichia coli O104:H4 associated with organic fenugreek sprouts, France, June 2011. Clin Infect Dis 2012; 54:1588 - 94; http://dx.doi.org/10.1093/cid/cis255; PMID: 22460976
   PubMed Web of Science ®Google Scholar
• Skurnik D, Davis MR Jr., Benedetti D, Moravec KL, Cywes-Bentley C, Roux D, et al. Targeting pan-resistant bacteria with antibodies to a broadly conserved surface polysaccharide expressed during infection. J Infect Dis 2012; 205:1709 - 18; http://dx.doi.org/10.1093/infdis/jis254; PMID: 22448004
   PubMed Web of Science ®Google Scholar
• Baer M, Sawa T, Flynn P, Luehrsen K, Martinez D, Wiener-Kronish JP, et al. An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity. Infect Immun 2009; 77:1083 - 90; http://dx.doi.org/10.1128/IAI.00815-08; PMID: 19103766
   PubMed Web of Science ®Google Scholar
• François B, Luyt CE, Dugard A, Wolff M, Diehl JL, Jaber S, et al. Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized,double-blind, placebo-controlled trial. Crit Care Med 2012; 40:2320 - 6; http://dx.doi.org/10.1097/CCM.0b013e31825334f6; PMID: 22622405
   PubMed Web of Science ®Google Scholar
• Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347:589 - 600; http://dx.doi.org/10.1056/NEJMra020528; PMID: 12192020
   PubMed Web of Science ®Google Scholar
• Menne J, Nitschke M, Stingele R, Abu-Tair M, Beneke J, Bramstedt J, et al, EHEC-HUS consortium. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 2012; 345:e4565; http://dx.doi.org/10.1136/bmj.e4565; PMID: 22815429
   PubMedGoogle Scholar
• Cacoub P, Delluc A, Saadoun D, Landau DA, Sene D. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand?. Ann Rheum Dis 2008; 67:283 - 7; http://dx.doi.org/10.1136/ard.2006.065565; PMID: 17644544
   PubMed Web of Science ®Google Scholar
• Visentini M, Ludovisi S, Petrarca A, Pulvirenti F, Zaramella M, Monti M, et al. A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection. Autoimmun Rev 2011; 10:714 - 9; http://dx.doi.org/10.1016/j.autrev.2011.04.033; PMID: 21570494
   PubMed Web of Science ®Google Scholar
• Petrarca A, Rigacci L, Caini P, Colagrande S, Romagnoli P, Vizzutti F, et al. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood 2010; 116:335 - 42; http://dx.doi.org/10.1182/blood-2009-11-253948; PMID: 20308604
   PubMed Web of Science ®Google Scholar
• Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, et al, B S R B R Control Centre Consortium, BSR Biologics Register. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010; 69:522 - 8; http://dx.doi.org/10.1136/ard.2009.118935; PMID: 19854715
   PubMed Web of Science ®Google Scholar
• Salmon-Ceron D, Tubach F, Lortholary O, Chosidow O, Bretagne S, Nicolas N, et al, RATIO group. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 2011; 70:616 - 23; http://dx.doi.org/10.1136/ard.2010.137422; PMID: 21177290
   PubMed Web of Science ®Google Scholar
• Van den Brande JMH, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s disease. Gastroenterology 2003; 124:1774 - 85; http://dx.doi.org/10.1016/S0016-5085(03)00382-2; PMID: 12806611
   PubMed Web of Science ®Google Scholar
• Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353:375 - 81; http://dx.doi.org/10.1056/NEJMoa051847; PMID: 15947078
   PubMed Web of Science ®Google Scholar
• Vermersch P, Kappos L, Gold R, Foley JF, Olsson T, Cadavid D, et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology 2011; 76:1697 - 704; http://dx.doi.org/10.1212/WNL.0b013e31821a446b; PMID: 21576685
   PubMed Web of Science ®Google Scholar
• Bozic C, Richman S, Plavina T, Natarajan A, Scanlon JV, Subramanyam M, et al. Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol 2011; 70:742 - 50; http://dx.doi.org/10.1002/ana.22606; PMID: 22162056
   PubMed Web of Science ®Google Scholar
• Rothstein DM, Sayegh MH. T-cell costimulatory pathways in allograft rejection and tolerance. Immunol Rev 2003; 196:85 - 108; http://dx.doi.org/10.1046/j.1600-065X.2003.00088.x; PMID: 14617200
   PubMed Web of Science ®Google Scholar
• Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10:535 - 46; http://dx.doi.org/10.1111/j.1600-6143.2009.03005.x; PMID: 20415897
   PubMed Web of Science ®Google Scholar